ANIP Ani Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP
  4. Earnings
Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 93

EPS in 2026 (TTM): $5.18

Last Report Period Date: Sep 30, 2026

As of November 2026, according to Ani Pharmaceuticals's latest financial report, the company's current EPS (TTM) is $5.18. In 2025, the company recorded an earnings per share (EPS) of $3.5, which represents an increase compared to its EPS of -$1.04 in 2024. Ani Pharmaceuticals's earnings per share for the quarterly report ending on Sep 30, 2026 was $1.54.

ANIP earnings history

Historical annual and quarterly earnings per share (EPS) data for Ani Pharmaceuticals
EPS (TTM)
$5.18
EPS Growth YoY (Quarterly)
29.4%
EPS (Quarterly)
$1.54
EPS Growth (Quarterly)
41.3%

The annual EPS in 2025 was $3.5, an increase of 436.5% from -$1.04 in 2024. For the quarter ending Sep 30, 2026, the EPS was $1.54, showing a 29.4% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2026 is $5.18. In 2024, the annual EPS was -$1.04, showing a decrease of 220.9% from 2023.

ANIP EPS vs price chart

ANIP EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
29.4%
EPS growth YoY
436.5%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the last 12 months, Ani Pharmaceuticals has registered an EPS growth of 29.4% (YoY, quarterly). A 10-year view shows that ANIP has seen an average EPS growth of 10.1% per year.

ANIP Earnings Waterfall

Breakdown of revenue, profit and net income for Ani Pharmaceuticals

ANIP Earnings vs Peers

What are the earnings of ANIP compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ANIP Ani Pharmaceuticals Inc 13.7 436.5% N/A N/A
NVS Novartis AG 30.53 21.8% 31.2% 15.2%
CAH Cardinal Health Inc 35.8 12.2% 78.9% 28.3%
PFE Pfizer Inc 40.7 -3.5% -37.4% -3.7%
RPRX Royalty Pharma plc - Class A 45.07 -6.8% 161.6% 6.3%
JAZZ Jazz Pharmaceuticals plc 66.04 -164.5% N/A N/A
TEVA Teva- Pharmaceutical Industries Ltd 97 184.8% N/A N/A
CLDX Celldex Therapeutics Inc N/A -59.2% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.